Literature DB >> 17201671

Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure.

Alejandro Vallejo1, Ezequiel Ruiz-Mateos, Sonia Molina-Pinelo, Natalia Soriano-Sarabia, Beatriz de Felipe, Sonia Gutierrez, Armando Sánchez-Quijano, Eduardo Lissen, Manuel Leal.   

Abstract

Immunovirologic parameters of 24 heavily antiretroviral drug-pretreated patients with prolonged virologic treatment failure under highly active antiretroviral therapy, and who harbored highly resistant human immunodeficiency virus (HIV) isolates, were studied in this retrospective cross-sectional study. Most of the patients were injecting drug users (71%) and male (88%). All patients were studied for CD4(+) cell count, HIV viral load, resistance mutations, and viral phenotype. The patients showed a high accumulation of resistance-associated mutations, their CD4(+) cell count and viral load directly correlated with their respective values at initiation of therapy, and the presence of K103N was inversely associated with lower viral load. On the other hand, patients with K103N had the same level of CD4(+) cell count compared with patients without this mutation. Among the patients, a majority with a specific viral phenotype was not present. Rather, a dual-tropic virus was found most frequently, suggesting a preferential suppression of X4-specific strains and less cytopathogenicity during antiretroviral therapy and a greater proportion of R5X4 viruses due to an adaptation to that pressure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201671     DOI: 10.1089/vim.2006.19.759

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  5 in total

1.  Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.

Authors:  A Gonzalez-Serna; R A McGovern; P R Harrigan; F Vidal; A F Y Poon; S Ferrando-Martinez; M A Abad; M Genebat; M Leal; E Ruiz-Mateos
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response.

Authors:  Inés Herrero-Fernández; Yolanda M Pacheco; Ezequiel Ruiz-Mateos; Manuel Leal; Miguel Genebat; María Del Mar Rodriguez-Méndez; María Del Carmen Lozano; María José Polaino; Isaac Rosado-Sánchez; Laura Tarancón-Diez; María Ángeles Muñoz-Fernández
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches.

Authors:  Alejandro Gonzalez-Serna; Manuel Leal; Miguel Genebat; Maria Antonia Abad; Antonio Garcia-Perganeda; Sara Ferrando-Martinez; Ezequiel Ruiz-Mateos
Journal:  J Clin Microbiol       Date:  2010-10-13       Impact factor: 5.948

4.  Effect of PEPFAR funding policy change on HIV service delivery in a large HIV care and treatment network in Nigeria.

Authors:  Bolanle Banigbe; Carolyn M Audet; Prosper Okonkwo; Olujide O Arije; Elizabeth Bassi; Kate Clouse; Melynda Simmons; Muktar H Aliyu; Kenneth A Freedberg; Aima A Ahonkhai
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

5.  Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA (LoViReTs).

Authors:  Cristina Gálvez; Víctor Urrea; Maria Del Carmen Garcia-Guerrero; Sílvia Bernal; Susana Benet; Beatriz Mothe; Lucía Bailón; Judith Dalmau; Andrea Martinez; Aroa Nieto; Lorna Leal; Felipe García; Bonaventura Clotet; Javier Martinez-Picado; Maria Salgado
Journal:  J Intern Med       Date:  2022-03-28       Impact factor: 13.068

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.